ClinicalTrials.gg
CompletedNCT01918332Updated Dec 15, 2014Results posted

Efficacy and Safety of Valsartan 160mg and Rosuvastatin 20mg in Patients With Hypertension and Hyperlipidemia

A Phase 3 interventional study of Valsartan 160mg and Rosuvastatin 20mg in Hypertension, and Hyperlipidemia, sponsored by LG Life Sciences. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-12-15.

Sponsored by LG Life Sciences (part of LG Chem) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
168
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 140 studies testing valsartan in Hypertension — none open to participants now, none under way, none of them phase 3. Valsartan · Hypertension.

Enrollment
72nd of 139
168 · median 198
Started
2012
with 4 others
Phase 3
53 of 140
none open now
Registered
122nd of 140
by date
Lead sponsor
3 of 140
LG Life Sciences

Among the 140 studies testing valsartan in Hypertension, this one is the 72nd largest by enrollment of the 139 interventional ones that give a count, is one of 5 that started in 2012, is one of 53 in phase 3, and was the 122nd registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

None of the 140 studies testing valsartan in Hypertension is open now. The open studies under Hypertension, anywhere →

About valsartan

Valsartan: first FDA approval 1996 (DIOVAN), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 140 studies testing valsartan in Hypertension as a file.
02

Study summary

This study aims to evaluate the efficacy and safety of the coadministration of valsartan (Diovan®) 160mg and rosuvastatin (Crestor®) 20mg in comparison to each component administered alone in patients with hypertension and hyperlipidemia.

03

Conditions studied

  • Hypertension,
  • Hyperlipidemia
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged 20-80 years who has hypertension and hyperlipidemia
  2. Patient who has a Hypertension
  3. Patient who has a Hyperlipidemia according to NCEP-ATP III guideline(2004)
  4. Patient who signed the Form after receiving an explanation on the purpose, methods, and effect of the study

Exclusion criteria

Exclusion Criteria:

  1. If blood pressure and fasting serum lipid level measured at screening and Visit 2 (0 week) satisfy the following criteria 1) sitSBP≥180mmHg or sitDBP≥110mmHg (For high risk group, sitSBP≥ 160mmHg or sitDBP ≥100mmHg ) 2) LDL-C>250mg/dL , or TG≥ 400mg/dL
  2. If sitSBP difference between the right and left arms >20mmHg or sitDBP difference between the right and left arms > 10mmHg at screening
  3. When blood pressure is repeatedly measured from the selected arm at screening, if sitSBP difference ≥ 20mmHg or sitDBP difference ≥10mmHg
  4. Patient with orthostatic hypotension accompanying symptoms at screening (decrease in sitDBP ≥10mmHg or decrease in sitSBP ≥ 20mmHg )
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
168 participants (actual)

Study arms

  • Experimental
    Valsartan 160mg, Rosuvastatin 20mg

    Both Valsartan 160mg and Rosuvastatin 20mg are administered daily by mouth once a day for 8 weeks.

    Drug: Valsartan 160mg · Drug: Rosuvastatin 20mg

  • Active comparator
    Valsartan 160mg, Rosuvastatin 20mg placebo

    Intervention : Drug : Both Valsartan 160mg and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.

    Drug: Valsartan 160mg · Drug: Rosuvastatin 20mg placebo

  • Active comparator
    Valsartan 160mg placebo, Rosuvastatin 20mg

    Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg are administered daily by p.o. once a day for 8 weeks.

    Drug: Rosuvastatin 20mg · Drug: Valsartan 160mg placebo

  • Placebo comparator
    Placebo

    Intervention : Drug : Both Valsartan 160mg placebo and Rosuvastatin 20mg placebo are administered daily by p.o. once a day for 8 weeks.

    Drug: Valsartan 160mg placebo · Drug: Rosuvastatin 20mg placebo

Interventions

06

What researchers measure

Primary outcomes

  1. sitDBP Changes at Week 8 From Baseline

    sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline

    Time frame: 8 weeks

  2. LDL-C Percentage Changes at Week 8 From Baseline

    LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline

    Time frame: 8 weeks

07

Results

Posted Dec 15, 2014
Limitations and caveats
Withdrawal(discontinuation) leading to smaller number of per-protocol set than full analysis set. The violation of protocol was the criterion of subjects' withdrawal.

Participant flow

Participant flow — Overall Study
MilestoneValsartan 160mg, Rosuvastatin 20mgValsartan 160mg, Rosuvastatin 20mg PlaceboValsartan 160mg Placebo, Rosuvastatin 20mgPlacebo
Started43413945
Completed35363038
Not completed8597
Withdrew: Adverse event0001
Withdrew: Withdrawal by subject2323
Withdrew: Protocol violation6263
Withdrew: Lipid result by central lab did not meet0010

Outcome measures

PrimarysitDBP Changes at Week 8 From Baseline

sitDBP changes of the valsartan 160mg and valsartan placebo groups at Week 8 from baseline

Time frame:
8 weeks
Reported as:
Least squares mean · mmHg
sitDBP Changes at Week 8 From Baseline
mmHgV160+R20 & V160R20 & Placebo
sitDBP Changes at Week 8 From Baseline-9.24 (-10.88 to -7.61)-2.9 (-4.55 to -1.24)
PrimaryLDL-C Percentage Changes at Week 8 From Baseline

LDL-C percentage changes of the rosuvastatin 20mg and rosuvastatin placebo groups at Week 8 from baseline

Time frame:
8 weeks
Reported as:
Least squares mean · percent change
LDL-C Percentage Changes at Week 8 From Baseline
percent changeV160+R20 & R20V160 & Placebo
LDL-C Percentage Changes at Week 8 From Baseline-49.91 (-53.34 to -46.47)-2.38 (-5.65 to 0.88)

Adverse events

Collected over 12~14 weeks (4-6 weeks of Therapeutic Lifestyle Change + 8 weeks of Treatment period). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Valsartan 160mg, Rosuvastatin 20mg—1/43 (2.3%)10/43 (23.3%)
Valsartan 160mg, Rosuvastatin 20mg Placebo—0/41 (0%)7/41 (17.1%)
Valsartan 160mg Placebo, Rosuvastatin 20mg—0/37 (0%)4/37 (10.8%)
Placebo—0/45 (0%)5/45 (11.1%)
Most frequent serious events
Most frequent serious events
EventValsartan 160mg, Rosuvastatin 20mgValsartan 160mg, Rosuvastatin 20mg PlaceboValsartan 160mg Placebo, Rosuvastatin 20mgPlacebo
NauseaGastrointestinal disorders1/430/410/370/45
Most frequent other events
Showing 10 of 24
Most frequent other events
EventValsartan 160mg, Rosuvastatin 20mgValsartan 160mg, Rosuvastatin 20mg PlaceboValsartan 160mg Placebo, Rosuvastatin 20mgPlacebo
headacheNervous system disorders2/430/410/373/45
dyspepsiaGastrointestinal disorders1/432/410/370/45
chest discomfortGeneral disorders0/432/410/370/45
dizzinessNervous system disorders1/432/410/370/45
nauseaGastrointestinal disorders2/430/410/370/45
conjunctival haemorrhageEye disorders0/430/411/370/45
astheniaGeneral disorders0/431/411/370/45
chest painGeneral disorders0/430/411/370/45
urinary tract infectionInfections and infestations0/430/411/370/45
alanine aminotransferase increasedInvestigations1/430/411/371/45

Baseline characteristics

Full Analysis Set

Age, Categorical
Age, Categorical(Participants)Valsartan 160mg, Rosuvastatin 20mgValsartan 160mg, Rosuvastatin 20mg PlaceboValsartan 160mg Placebo, Rosuvastatin 20mgPlaceboTotal
<=18 years00000
Between 18 and 65 years26242129100
>=65 years1516141560
Sex: Female, Male
Sex: Female, Male(Participants)Valsartan 160mg, Rosuvastatin 20mgValsartan 160mg, Rosuvastatin 20mg PlaceboValsartan 160mg Placebo, Rosuvastatin 20mgPlaceboTotal
Female161471047
Male25262834113
08

Study locations

1 site
  • Yonsei University Health System Severance Hospital
    Seoul, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 1 year 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2013
First posted
Aug 7, 2013
Start
Apr 2012
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Dec 15, 2014
Last update
Dec 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01918332
Lead sponsor
LG Life Sciences
Responsible party
Sponsor
First posted
Aug 7, 2013
Start date
Apr 2012
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Dec 15, 2014
Last update
Dec 15, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Valsartan · Rosuvastatin

Start the discussion